The Dundalk site provides drug substance and product manufacturing, as well as quality control capabilities. Credit: Comezora via Getty Images. WuXi Biologics subsidiary WuXi Vaccines has agreed to ...

China's WuXi Biologics is to sell its vaccine manufacturing site in Dundalk to MSD Ireland in a €500m deal. The acquisition is expected to be completed in the first half of this year and will ...

News that pharmaceutical company MSD Ireland has acquired the WuXi Vaccines manufacturing facility in Dundalk has been welcomed by Louth TDs Paula Butterly and Erin McGreehan.

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering impactful support to St. Vincent de Paul Dundalk through their fourth annual ...

The pharmaceutical firm MSD is buying out the WuXi Vaccines manufacturing plant in Dundalk, in a €500m deal. The American company says that in addition to the 150 jobs at the Dundalk facility ...

Pharmaceutical firm MSD has agreed a deal to buy the WuXi Vaccines manufacturing facility in Dundalk, Co Louth as part of its long-term plans in Ireland. MSD said the deal is worth €500m and ...

The employees at WuXi Biologics have once again shown their commitment to the local community with their fourth annual Christmas appeal for the St. Vincent de Paul Society in Dundalk. Continuing ...

WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025 ...

The Dundalk site was WuXi's first manufacturing investment in Europe and the company’s first investment of this scale outside of China The MSD site in Dundalk, Co Louth. The Dundalk site will ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...